Health-related quality of life in patients aged 6-18 years with chronic hepatitis C treated with sofosbuvir/velpatasvir.

Maria Pokorska-ŚpiewakEwa TalarekMałgorzata AniszewskaMagdalena PlutaAnna DobrzenieckaMagdalena MarczyńskaGiuseppe Indolfi

Published in: Liver international : official journal of the International Association for the Study of the Liver (2023)

A significant proportion of children with chronic hepatitis C have decreased HRQL in all dimensions, but effective treatment with SOF/VEL leads to an improvement in some areas of well-being. As the effect of HCV on HRQL is more pronounced in older patients, treatment of younger children should be indicated to prevent them from experiencing decreased HRQL due to ongoing HCV infection in the future.

Keyphrases

hepatitis c virus
end stage renal disease
young adults
newly diagnosed
ejection fraction
chronic kidney disease
human immunodeficiency virus
peritoneal dialysis
combination therapy
patient reported outcomes
current status
hiv infected